HIV-1 Env DNA Vaccine plus Protein Boost Delivered by EP Expands B- and T-Cell Responses and Neutralizing Phenotype In Vivo

An effective HIV vaccine will most likely require the induction of strong T-cell responses, broadly neutralizing antibodies (bNAbs), and the elicitation of antibody-dependent cellular cytotoxicity (ADCC). Previously, we demonstrated the induction of strong HIV/SIV cellular immune responses in macaques and humans using synthetic consensus DNA immunogens delivered via adaptive electroporation (EP). However, the ability of this improved DNA approach to prime for relevant antibody responses has not been previously studied. Here, we investigate the immunogenicity of consensus DNA constructs encoding gp140 sequences from HIV-1 subtypes A, B, C and D in a DNA prime-protein boost vaccine regimen. Mice and guinea pigs were primed with single- and multi-clade DNA via EP and boosted with recombinant gp120 protein. Sera were analyzed for gp120 binding and induction of neutralizing antibody activity. Immunization with recombinant Env protein alone induced low-titer binding antibodies with limited neutralization breath. In contrast, the synthetic DNA prime-protein boost protocol induced significantly higher antibody binding titers. Furthermore, sera from DNA prime-protein boost groups were able to neutralize a broader range of viruses in a panel of tier 1 clade B viruses as well as multiple tier 1 clade A and clade C viruses. Further investigation of synthetic DNA prime plus adaptive EP plus protein boost appears warranted.

[1]  Donald K Carter,et al.  Safety and comparative immunogenicity of an HIV-1 DNA vaccine in combination with plasmid interleukin 12 and impact of intramuscular electroporation for delivery. , 2013, The Journal of infectious diseases.

[2]  N. Sardesai,et al.  Immunotherapy Against HPV16/18 Generates Potent TH1 and Cytotoxic Cellular Immune Responses , 2012, Science Translational Medicine.

[3]  D. Weiner,et al.  Intradermal DNA vaccination enhanced by low-current electroporation improves antigen expression and induces robust cellular and humoral immune responses. , 2012, Human gene therapy.

[4]  Hasan Ahmed,et al.  Magnitude and Breadth of the Neutralizing Antibody Response in the RV144 and Vax003 HIV-1 Vaccine Efficacy Trials , 2012, The Journal of infectious diseases.

[5]  N. Sardesai,et al.  Hepatitis C virus NS3/NS4A DNA vaccine induces multiepitope T cell responses in rhesus macaques mimicking human immune responses [corrected]. , 2012, Molecular therapy : the journal of the American Society of Gene Therapy.

[6]  W. Blattner,et al.  Safety and Immunogenicity of an HIV-1 Gag DNA Vaccine with or without IL-12 and/or IL-15 Plasmid Cytokine Adjuvant in Healthy, HIV-1 Uninfected Adults , 2012, PloS one.

[7]  Susan Moir,et al.  Prospects for an HIV vaccine: leading B cells down the right path , 2011, Nature Structural &Molecular Biology.

[8]  D. Weiner,et al.  Molecular adjuvant HMGB1 enhances anti-influenza immunity during DNA vaccination , 2011, Gene Therapy.

[9]  N. Sardesai,et al.  Immunogenicity of a novel engineered HIV-1 clade C synthetic consensus-based envelope DNA vaccine. , 2011, Vaccine.

[10]  Bette T. Korber,et al.  Converging on an HIV Vaccine , 2011, Science.

[11]  D. Weiner,et al.  HIV-Mediated Phosphatidylinositol 3-Kinase/Serine–Threonine Kinase Activation in APCs Leads to Programmed Death-1 Ligand Upregulation and Suppression of HIV-Specific CD8 T Cells , 2011, The Journal of Immunology.

[12]  N. Sardesai,et al.  High antibody and cellular responses induced to HIV-1 clade C envelope following DNA vaccines delivered by electroporation. , 2011, Vaccine.

[13]  N. Sardesai,et al.  A highly optimized DNA vaccine confers complete protective immunity against high-dose lethal lymphocytic choriomeningitis virus challenge. , 2011, Vaccine.

[14]  D. Montefiori,et al.  A trimeric, V2-deleted HIV-1 envelope glycoprotein vaccine elicits potent neutralizing antibodies but limited breadth of neutralization in human volunteers. , 2011, The Journal of infectious diseases.

[15]  D. Weiner,et al.  Prototype development and preclinical immunogenicity analysis of a novel minimally invasive electroporation device , 2011, Gene Therapy.

[16]  N. Sardesai,et al.  A DNA Vaccine against Chikungunya Virus Is Protective in Mice and Induces Neutralizing Antibodies in Mice and Nonhuman Primates , 2011, PLoS neglected tropical diseases.

[17]  D. Cooper,et al.  AIDS Vaccine for Asia Network (AVAN): Expanding the Regional Role in Developing HIV Vaccines , 2010, PLoS medicine.

[18]  N. Sardesai,et al.  IL-28B/IFN-λ3 Drives Granzyme B Loading and Significantly Increases CTL Killing Activity in Macaques. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

[19]  Mario Roederer,et al.  Rational Design of Envelope Identifies Broadly Neutralizing Human Monoclonal Antibodies to HIV-1 , 2010, Science.

[20]  Tongqing Zhou,et al.  Structural Basis for Broad and Potent Neutralization of HIV-1 by Antibody VRC01 , 2010, Science.

[21]  Dennis R Burton,et al.  A Boost for HIV Vaccine Design , 2010, Science.

[22]  N. Sardesai,et al.  Comparative analysis of immune responses induced by vaccination with SIV antigens by recombinant Ad5 vector or plasmid DNA in rhesus macaques. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

[23]  Timothy Cardozo,et al.  Structure–function relationships of HIV-1 envelope sequence-variable regions refocus vaccine design , 2010, Nature Reviews Immunology.

[24]  David C Montefiori,et al.  The role of antibodies in HIV vaccines. , 2010, Annual review of immunology.

[25]  Laurie Lamoreaux,et al.  Priming Immunization with DNA Augments Immunogenicity of Recombinant Adenoviral Vectors for Both HIV-1 Specific Antibody and T-Cell Responses , 2010, PloS one.

[26]  D. Montefiori,et al.  Breadth of Neutralizing Antibodies Elicited by Stable, Homogeneous Clade A and Clade C HIV-1 gp140 Envelope Trimers in Guinea Pigs , 2010, Journal of Virology.

[27]  Holly Janes,et al.  Tiered Categorization of a Diverse Panel of HIV-1 Env Pseudoviruses for Assessment of Neutralizing Antibodies , 2009, Journal of Virology.

[28]  D. Weiner,et al.  High dose of plasmid IL-15 inhibits immune responses in an influenza non-human primates immunogenicity model. , 2009, Virology.

[29]  D. Weiner,et al.  Monkeying around with HIV vaccines: using rhesus macaques to define 'gatekeepers' for clinical trials , 2009, Nature Reviews Immunology.

[30]  D. Weiner,et al.  Novel SIVmac DNA vaccines encoding Env, Pol and Gag consensus proteins elicit strong cellular immune responses in cynomolgus macaques. , 2009, Vaccine.

[31]  D. Weiner,et al.  Electroporation of Synthetic DNA Antigens Offers Protection in Nonhuman Primates Challenged with Highly Pathogenic Avian Influenza Virus , 2009, Journal of Virology.

[32]  Michele A. Kutzler,et al.  DNA vaccines: ready for prime time? , 2008, Nature Reviews Genetics.

[33]  D. Weiner,et al.  Cellular immunity induced by a novel HPV18 DNA vaccine encoding an E6/E7 fusion consensus protein in mice and rhesus macaques. , 2008, Vaccine.

[34]  N. Sardesai,et al.  Immunogenicity of novel consensus-based DNA vaccines against Chikungunya virus. , 2008, Vaccine.

[35]  N. Sardesai,et al.  Heterosubtypic Protection against Pathogenic Human and Avian Influenza Viruses via In Vivo Electroporation of Synthetic Consensus DNA Antigens , 2008, PloS one.

[36]  David C Montefiori,et al.  Recent advances in the characterization of HIV-1 neutralization assays for standardized evaluation of the antibody response to infection and vaccination. , 2008, Virology.

[37]  T. Waldmann,et al.  Protection against simian/human immunodeficiency virus (SHIV) 89.6P in macaques after coimmunization with SHIV antigen and IL-15 plasmid , 2007, Proceedings of the National Academy of Sciences.

[38]  Gary J. Nabel,et al.  No Evidence for Consistent Virus-Specific Immunity in Simian Immunodeficiency Virus-Exposed, Uninfected Rhesus Monkeys , 2007, Journal of Virology.

[39]  M. Ramanathan,et al.  Enhanced cellular immune responses elicited by an engineered HIV-1 subtype B consensus-based envelope DNA vaccine. , 2007, Molecular therapy : the journal of the American Society of Gene Therapy.

[40]  M. Ramanathan,et al.  Immunogenicity testing of a novel engineered HIV-1 envelope gp140 DNA vaccine construct. , 2006, DNA and cell biology.

[41]  J. Mascola,et al.  Polyvalent HIV-1 Env vaccine formulations delivered by the DNA priming plus protein boosting approach are effective in generating neutralizing antibodies against primary human immunodeficiency virus type 1 isolates from subtypes A, B, C, D and E. , 2006, Virology.

[42]  Crafford A. Harris,et al.  HIV-1 Nef-induced FasL induction and bystander killing requires p38 MAPK activation. , 2005, Blood.

[43]  T. Waldmann,et al.  Coimmunization with an Optimized IL-15 Plasmid Results in Enhanced Function and Longevity of CD8 T Cells That Are Partially Independent of CD4 T Cell Help3 , 2005, The Journal of Immunology.

[44]  Scott A. Brown,et al.  Clustering of Th Cell Epitopes on Exposed Regions of HIV Envelope Despite Defects in Antibody Activity 1 , 2003, The Journal of Immunology.

[45]  D. Weiner,et al.  Novel engineered HIV-1 East African Clade-A gp160 plasmid construct induces strong humoral and cell-mediated immune responses in vivo. , 2003, Virology.

[46]  L. Stamatatos,et al.  Envelope-Based HIV Vaccines , 2002, Science.

[47]  W. Hall,et al.  Continuous epitopes of the human immunodeficiency virus type 1 (HIV-1) transmembrane glycoprotein and reactivity of human sera to synthetic peptides representing various HIV-1 isolates , 1991, Journal of virology.

[48]  N. Sardesai,et al.  Hepatitis C Virus NS3/NS4A DNA Vaccine Induces Multiepitope T Cell Responses in Rhesus Macaques Mimicking Human Immune Responses. , 2012, Molecular therapy : the journal of the American Society of Gene Therapy.

[49]  N. Sardesai,et al.  Multivalent smallpox DNA vaccine delivered by intradermal electroporation drives protective immunity in nonhuman primates against lethal monkeypox challenge. , 2011, The Journal of infectious diseases.

[50]  N. Sardesai,et al.  IL-28B/IFN-lambda 3 drives granzyme B loading and significantly increases CTL killing activity in macaques. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

[51]  M. Kutzler,et al.  Plasmids encoding the mucosal chemokines CCL27 and CCL28 are effective adjuvants in eliciting antigen-specific immunity in vivo , 2010, Gene Therapy.